Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Regulation FD DisclosureItem 7.01
The information in this Current Report is being furnished to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement to the Securities Act of 1933, as amended.
Representatives of Repros Therapeutics Inc., a Delaware corporation (the “Company”) are presenting updates on the Company’s Proellex® and Enclomiphene clinical programs to various investors and other interested parties September 11 through September 13, 2017, in New York, NY, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. These slides contain statements that are “forward-looking statements” subject to the cautionary statement about forward-looking statements set forth therein.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Repros Therapeutics Slideshow|
REPROS THERAPEUTICS INC. ExhibitEX-99.1 2 v474892_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 REPROS THERAPEUTICS Corporate Presentation September 2017 Dedicated to Treating Male and Female Reproductive Disorders Safe Harbor Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward – looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks,…To view the full exhibit click
About Repros Therapeutics Inc. (NASDAQ:RPRX)
Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.